New research led by the University of Manchester in the UK has found a biomarker or molecular "flag" in women with breast cancer who do not repond, or who have become resistant, to treatment with the hormone drug tamoxifen. The researchers say their discovery will help doctors predict which breast cancer patients are likely to respond best to complementary (adjuvant) hormone therapy with tamoxifen...
More...
More...